63.66
Sarepta Therapeutics Inc 주식(SRPT)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of HealthEquity, Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sarepta ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sarepta Therapeutics, Inc. - GlobeNewswire Inc.
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus
Oligonucleotide Delivery System Market Key Players Analysis - openPR.com
Earnings To Watch: Sarepta Therapeutics (SRPT) Reports Q1 Results Tomorrow - Yahoo Finance
Ratios Revealed: Decoding Sarepta Therapeutics Inc (SRPT)’s Financial Health - DWinneX
Sarepta Therapeutics Inc [SRPT] stock for 248,203 USD was sold by Nicaise Claude - knoxdaily.com
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth - MSN
Duchenne Muscular Dystrophy Market Forecasted to Surge - openPR.com
Adversity is less terrifying than hope: Sarepta Therapeutics Inc (SRPT) - Sete News
Why Sarepta Therapeutics, Inc. (SRPT) is Among the Best Oversold NASDAQ Stocks to Buy Right Now - Yahoo Finance
11 Oversold NASDAQ Stocks to Buy Right Now - Insider Monkey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sarepta Therapeutics, Inc. – SRPT - TradingView
Sarepta Therapeutics Inc (SRPT) did well last session? - uspostnews.com
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, In - GuruFocus
Recent Insider Activity Suggests Potential Gains for Sarepta Therapeutics Inc (SRPT) - knoxdaily.com
Press Release Distribution & PR Platform - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta - Bluefield Daily Telegraph
Sarepta Therapeutics Inc (SRPT)’s Market Momentum: Closing Strong at 59.49, Up 0.30 - DWinneX
Cns Specific Antisense Oligonucleotide Market Generated - openPR.com
Sarepta Therapeutics (SRPT): Among Billionaire George Soros’ Small-Cap Stocks with Huge Upside Potential - MSN
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Cerity Partners LLC - Defense World
How To Trade (SRPT) - news.stocktradersdaily.com
Billionaire George Soros’ 10 Small-Cap Stocks with Huge Upside Potential - Insider Monkey
Get in on Sarepta Therapeutics Inc’s (SRPT) buy-in window today! - Sete News
Why Do Investors Buy Stock In Sarepta Therapeutics Inc (SRPT)? - Marketing Sentinel
Sarepta Therapeutics Inc [SRPT] Stock sold by Insider Nicaise Claude for $0.25 million - knoxdaily.com
SRPT Quantitative Stock Analysis - Nasdaq
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
Sarepta: Gene therapy Elevidys has given ‘hope’ to DMD community - Muscular Dystrophy News
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost - MSN
Sarepta Therapeutics Inc (SRPT) produces promising results - uspostnews.com
Sarepta Therapeutics to Announce First Quarter 2025 Financial Re - GuruFocus
Sarepta Therapeutics to Announce First Quarter 2025 Financial Results | SRPT Stock News - GuruFocus
Sarepta Therapeutics To Announce First Quarter 2025 Financial Results - marketscreener.com
Sarepta Therapeutics to Announce First Quarter 2025 Financial Results - Business Wire
Envestnet Asset Management Inc. Boosts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Short Interest Update - Defense World
Sarepta Therapeutics (NASDAQ:SRPT) Given New $110.00 Price Target at Piper Sandler - Defense World
Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Long-Term Stock According to Analysts? - Insider Monkey
ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
11 Most Promising Long-Term Stocks According to Analysts - Insider Monkey
Netflix To Rally More Than 55%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Piper Sandler Cuts Price Target for Sarepta (SRPT) Amid Elevidys Sales Concerns | SRPT Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Thera - NatLawReview.com
Sarepta (SRPT) Price Target Lowered by BofA Ahead of Q1 Earnings | SRPT Stock News - GuruFocus
자본화:
|
볼륨(24시간):